Trial Profile
Pilot, Phase 2 Study Assessing Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm(EGFR Mutation) NSCLC Patients With Asymptomatic Brain Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Sep 2021 Preliminary analysis (n=13) presented at the 46th European Society for Medical Oncology Congress
- 29 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 13 May 2020 Planned End Date changed from 1 May 2020 to 31 Dec 2022.